Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.70 |
| ▸ | RARA | P10276 | 6/20 | 0.70 |
| ▸ | RXRA | P19793 | 5/20 | 0.70 |
| ▸ | RARB | P10826 | 4/20 | 0.70 |
| ▸ | RARG | P13631 | 4/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.70 |
| ▸ | RXRB | P28702 | 2/20 | 0.70 |
| ▸ | RXRG | P48443 | 2/20 | 0.70 |
| ▸ | RORC | P51449 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | HTR2B | P41595 | 2/20 | 0.70 |
| ▸ | BLM | P54132 | 2/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | DRD3 | P35462 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1578435 | 1.00 | MAPT (0.81) | MAPTALOX15ALDH1A1RARARXRA | |
| SCHEMBL3708856 | 1.00 | MAPT (0.81) | MAPTALOX15ALDH1A1RARARXRA | |
| SCHEMBL9007198 | 1.00 | MAPT (0.81) | MAPTALOX15ALDH1A1RARARXRA | |
| SCHEMBL3334775 | 1.00 | MAPT (0.81) | MAPTALOX15ALDH1A1RARARXRA | |
| SCHEMBL1578472 | 1.00 | MAPT (0.81) | MAPTALOX15ALDH1A1RARARXRA | |
| SCHEMBL161113 | 1.00 | MAPT (0.81) | MAPTALOX15ALDH1A1RARARXRA | |
| SCHEMBL3502557 | 1.00 | MAPT (0.81) | MAPTALOX15ALDH1A1RARARXRA | |
| SCHEMBL12494856 | 0.92 | MAPT (0.68) | MAPTALOX15ALDH1A1RARARXRA | |
| SCHEMBL17099746 | 0.92 | MAPT (0.68) | MAPTALOX15ALDH1A1RARARXRA | |
| SCHEMBL25378972 | 0.90 | MAPT (0.81) | MAPTALOX15ALDH1A1RARARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000741-A1 | ALL-TRANS RETINOIC ACID ENHANCES RADIOTHERAPY AND OVERCOMES IMMUNE SUPPRESSION FOR CANCER THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-04 | — | — | US | claimed |
| EP-3987290-A1 | SERIES OF METABOLITES AS BIOMARKERS FOR THE DIAGNOSIS OF PANCREATIC CANCER | Universidad de Granada (ES) | 2022-04-27 | — | — | EP | claimed |
| WO-2020254667-A1 | SERIES OF METABOLITES AS BIOMARKERS FOR THE DIAGNOSIS OF PANCREATIC CANCER | UNIVERSIDAD DE GRANADA (ES) | 2020-12-24 | — | — | WO | claimed |
| US-7759069-B1 | Compositions and methods for measuring nuclear receptor ligands | CORNELL RESEARCH FOUNDATION, INC. (US) | 2010-07-20 | — | — | US | claimed |
| US-20090304614-A1 | Use of Polyunsaturated Compounds as Whitening Agents | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2009-12-10 | — | — | US | claimed |
| US-20080027031-A1 | Retinoids and Related Compounds for the Treatment of Neuroinflammatory Conditions, Diseases and Disorders | KINEMED, INC. (US) | 2008-01-31 | — | — | US | claimed |
| US-20060281813-A1 | Methods of treating hyperproliferative cell disorders | RUBIN CHARLES | 2006-12-14 | — | — | US | claimed |
| EP-1628631-A2 | METHODS OF TREATING HYPERPROLIFERATIVE CELL DISORDERS | Achkar, Charles C. (US) | 2006-03-01 | — | — | EP | claimed |
| EP-1104294-B8 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | LEO PHARMA AS (DK) | 2005-11-23 | — | — | EP | claimed |
| WO-2005000230-A2 | METHODS OF TREATING HYPERPROLIFERATIVE CELL DISORDERS | ACHKAR CHARLES (US) | 2005-01-06 | — | — | WO | claimed |
| EP-1104294-A1 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | Achkar, Charles C. (US) | 2001-06-06 | — | — | EP | claimed |
| WO-2000003700-A1 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | ACHKAR CHARLES C (US) | 2000-01-27 | — | — | WO | claimed |
| EP-0071598-B1 | THE USE OF RETINOIDS AND THEIR DERIVATIVES TO INCREASE THE RATE OF GROWTH OF HUMAN SCALP HAIR AND TO INCREASE THE RATE OF GROWTH OF FUR IN CERTAIN FURBEARING ANIMALS | BAZZANO, Gail S (US) | 1990-05-09 | — | — | EP | claimed |
| EP-0093770-A4 | THE USE OF RETINOIDS AND MINOXIDIL (2,4-DIAMINO-6-PIPERIDINO-PYRIMIDINE-3-OXIDE) TO INCREASE THE RATE OF GROWTH OF HUMAN SCALP HAIR AND TO TREAT CERTAIN TYPES OF ALOPECIAS. | BAZZANO GAIL S | 1987-11-25 | — | — | EP | claimed |
| EP-0093770-A1 | THE USE OF RETINOIDS AND MINOXIDIL (2,4-DIAMINO-6-PIPERIDINO-PYRIMIDINE-3-OXIDE) TO INCREASE THE RATE OF GROWTH OF HUMAN SCALP HAIR AND TO TREAT CERTAIN TYPES OF ALOPECIAS. | BAZZANO GAIL S | 1983-11-16 | — | — | EP | claimed |
| WO-1983002558-A1 | THE USE OF RETINOIDS AND MINOXIDIL (2,4,-DIAMINO-6-PIPERIDINO-PYRIMIDINE-3-OXIDE) TO INCREASE THE RATE OF GROWTH OF HUMAN SCALP HAIR AND TO TREAT CERTAIN TYPES OF ALOPECIAS | BAZZANO, GAIL, SANSONE | 1983-08-04 | — | — | WO | claimed |
| EP-0071598-A4 | THE USE OF RETINOIDS AND THEIR DERIVATIVES TO INCREASE THE RATE OF GROWTH OF HUMAN SCALP HAIR AND TO INCREASE THE RATE OF GROWTH OF FUR IN CERTAIN FURBEARING ANIMALS. | BAZZANO GAIL S | 1983-06-08 | — | — | EP | claimed |
| EP-0071598-A1 | THE USE OF RETINOIDS AND THEIR DERIVATIVES TO INCREASE THE RATE OF GROWTH OF HUMAN SCALP HAIR AND TO INCREASE THE RATE OF GROWTH OF FUR IN CERTAIN FURBEARING ANIMALS. | BAZZANO GAIL S | 1983-02-16 | — | — | EP | claimed |
| WO-1982002833-A1 | THE USE OF RETINOIDS AND THEIR DERIVATIVES TO INCREASE THE RATE OF GROWTH OF HUMAN SCALP HAIR AND TO INCREASE THE RATE OF GROWTH OF FUR IN CERTAIN FUR-BEARING ANIMALS | BAZZANO GAIL SANSONE | 1982-09-02 | — | — | WO | claimed |
| EP-0004680-A2 | Derivative nonatetraenoic acid and pharmaceutical compositions | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-10-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281813-A1 | Methods of treating hyperproliferative cell disorders | HRAS, CDC73, MKI67 | MAPT 4706/4885ALOX15 1556/4885ALDH1A1 1302/4885 |
| US-20080027031-A1 | Retinoids and Related Compounds for the Treatment of Neuroinflammatory Conditions, Diseases and Disorders | RARA, RARB, RXRA | MAPT 404/4885ALOX15 341/4885ALDH1A1 904/4885 |
| US-20090304614-A1 | Use of Polyunsaturated Compounds as Whitening Agents | FASN, ALOX5, ALOX15B | MAPT 2405/4885ALOX15 5/4885ALDH1A1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.